Presentation and Real-World Management of Giant Cell Arteritis (Artemis Study). - Université de Lille Accéder directement au contenu
Article Dans Une Revue Frontiers in Medicine Année : 2021

Presentation and Real-World Management of Giant Cell Arteritis (Artemis Study).

L. Sailler
  • Fonction : Auteur
I. Idier
  • Fonction : Auteur


Background: Few studies of daily practice for patients with giant cell arteritis (GCA) are available. This French study aimed to describe the characteristics and management of GCA in a real-life setting. Methods: Cross-sectional, non-interventional, multicenter study of patients ≥50 years old who consulted hospital-based specialists for GCA and were under treatment. Patient characteristics and journey, diagnostic methods and treatments were collected. Descriptive analyses were performed. Results: In total, 306 patients (67% females, mean age 74 ± 8 years old) were recruited by 69 physicians (internists: 85%, rheumatologists: 15%); 13% of patients had newly diagnosed GCA (diagnosis-to-visit interval <6 weeks). Overall median disease duration was 13 months (interquartile range 5–26). Most patients were referred by general practitioners (56%), then ophthalmologists (10%) and neurologists (7%). Most common comorbidities were hypertension (46%), psychiatric disorders (10%), dyslipidemia (12%), diabetes (9%), and osteoporosis (6%). Initial GCA presentations included cranial symptoms (89%), constitutional symptoms (74%), polymyalgia rheumatica (48%), and/or other extra-cranial manifestations (35%). Overall, 85, 31, 26, and 30% of patients underwent temporal artery biopsy, high-resolution temporal artery Doppler ultrasonography, 18FDG-PET, and aortic angio-CT, respectively. All patients received glucocorticoids, which were ongoing for 89%; 29% also received adjunct medication(s) (methotrexate: 19%, tocilizumab: 15%). A total of 40% had relapse(s); the median time to the first relapse was 10 months. Also, 37% had comorbidity(ies) related to or aggravated by glucocorticoids therapy. Conclusion: This large observational study provides insight into current medical practices for GCA. More than one third of patients had comorbidities related to glucocorticoid therapy for a median disease duration of 13 months. Methotrexate and tocilizumab were the most common adjunct medications.
Fichier principal
Vignette du fichier
fmed-08-732934 (1).pdf (508.62 Ko) Télécharger le fichier
Origine Publication financée par une institution

Dates et versions

hal-04479309 , version 1 (28-02-2024)




A. Mahr, Eric Hachulla, H. de Boysson, N. Guerroui, E. Héron, et al.. Presentation and Real-World Management of Giant Cell Arteritis (Artemis Study).. Frontiers in Medicine, 2021, Frontiers in Medicine, 8, pp.732934. ⟨10.3389/fmed.2021.732934⟩. ⟨hal-04479309⟩
18 Consultations
6 Téléchargements



Gmail Mastodon Facebook X LinkedIn More